MARKER THERAPEUTICS INC (MRKR)

US57055L2060 - Common Stock

4.22  +0.02 (+0.48%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2027 2028 2029 2030 2031
Revenue
YoY % growth
1.24M
163.83%		9.01M
626.61%		3.311M
-63.25%
EBITDA
YoY % growth
-37.32M
-31.41%		-27.16M
27.22%		N/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
-39.47M
-36.62%		-29.95M
24.12%		-14.581M
51.31%		N/AN/AN/AN/A
Operating Margin
-3,183.06%-332.41%-440.37%N/AN/AN/AN/A
EPS
YoY % growth
-3.86
-522.58%		-3.58
7.25%		N/AN/AN/AN/AN/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2022
Q2Q % growth		 -0.48
60.00%		-1.020.5452.94%
Q3 2022
Q2Q % growth		 -0.80
33.33%		-1.220.4234.64%
Q2 2022
Q2Q % growth		 -1.10
15.38%		-1.290.1914.86%
Q1 2022
Q2Q % growth		 -1.20
-650.00%		-1.360.1611.76%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 1.057M
-68.08%		1.057M∞%
Q3 2023
Q2Q % growth		 260K
-74.00%		260K∞%
Q2 2023
Q2Q % growth		 760K
-3.80%		760K∞%
Q1 2023
Q2Q % growth		 1.23M
28.13%		1.23M∞%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A N/A N/A
RevenueN/A N/A N/A N/A